Biopharmas raised $5.87 billion through 96 financings transactions in July 2023. The total amount raised is similar to the first six months of 2023 average of $5.48 billion per month, ranging from $3.74 billion in February to $8.02 billion in March of this year. Including July, the 2023 monthly average of money raised in all transactions is $5.46 billion.
Med-tech companies raised $955 million from 40 transactions in July 2023, a decrease of 12.39% from the $1.09 billion raised in July 2022. The volume of med-tech financings has increased from 32 in July 2022, though it is less than the previous six months’ average of 43 and seven-month average of 42. Compared to prior years, July 2021 saw $4.78 billion raised in 74 financings, $3.15 billion from 80 transactions in July 2020 and $1.99 billion from 41 financings in July 2019.
Clinical data in the first half of 2023 is up 1.51% compared to the same time period last year. So far in 2023 BioWorld reported on 1,810 drugs in phase I-III, compared to 1,783 in the first half of 2022. The number of trial updates is down 13.6% from the 2,095 in 2021, but more than 2020’s 1,799 and 2019’s 1,477.
Broadly neutralizing antibodies (bNAbs) have the potential to prevent HIV, and more researchers are turning to bNAbs as an alternative to antiretroviral therapy (ART), speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. However, for a cure, the viral reservoir that is formed in the early stages of HIV remains an obstacle, and recent studies suggest that controlling or eliminating the HIV reservoir with bNAbs might be possible.